Piana JL, Martino R, Garca-Garca I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21 https://doi.org/10.1186/s40164-020-00177-z

Article CAS PubMed PubMed Central Google Scholar

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:288594. https://doi.org/10.1038/s41375-021-01302-5

Article CAS PubMed PubMed Central Google Scholar

Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35:35858. https://doi.org/10.1038/s41375-021-01466-0

Article CAS PubMed PubMed Central Google Scholar

Piana JL, Lpez-Corral L, Martino R, Montoro J, Vazquez L, Prez A, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022;97:3042. https://doi.org/10.1002/ajh.26385

Article CAS PubMed Google Scholar

Piana JL, Lpez-Corral L, Martino R, Vazquez L, Prez A, Martin-Martin G, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J Hematol Oncol. 2022;15:54 https://doi.org/10.1186/s13045-022-01275-7. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)

Article CAS PubMed PubMed Central Google Scholar

Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood. 2022;140:44550. https://doi.org/10.1182/blood.2022016147

Article CAS PubMed PubMed Central Google Scholar

Leclerc M, Redjoul R, Le Bouter A, Beckerich F, Robin C, Parinet V, et al. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. J Hematol Oncol. 2022;15:27 https://doi.org/10.1186/s13045-022-01250-2

Article CAS PubMed PubMed Central Google Scholar

Carreo JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 omicron. Nature. 2022;602:6828. https://doi.org/10.1038/s41586-022-04399-5

Article CAS PubMed Google Scholar

Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl J Med. 2022;386:4924. https://doi.org/10.1056/NEJMc2119358

Article PubMed Google Scholar

Collier AY, Yu J, McMahan K, Liu J, Atyeo C, Ansel JL, et al. Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. J Infect Dis. 2022;225:11248. https://doi.org/10.1093/infdis/jiab569

Article CAS PubMed Google Scholar

Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36:146780. https://doi.org/10.1038/s41375-022-01578-1

Article CAS PubMed PubMed Central Google Scholar

Piana JL, Rodrguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, et al. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Ann Hematol. 2022;101(Sep):205367. https://doi.org/10.1007/s00277-022-04906-8

Article CAS PubMed Google Scholar

Piana JL, Vzquez L, Martino R, de la Cmara R, Sureda A, Rodrguez-Veiga R, et al. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leuk Lymphoma. 2022;63:53850. https://doi.org/10.1080/10428194.2021.1992619

Article CAS PubMed Google Scholar

Piana JL, Vazquez L, Calabuig M, Lpez-Corral L, Martin-Martin G, Villalon L, et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 2023;13:8 https://doi.org/10.1038/s41408-022-00778-3. Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)

Article PubMed PubMed Central Google Scholar

https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20220523.pdf

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695706. 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O

Article CAS PubMed Google Scholar

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 2012;94:496509. https://doi.org/10.1080/01621459.1999.10474144

Article Google Scholar

Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:114154. https://doi.org/10.1214/aos/1176350951

Article Google Scholar

Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc Natl Acad Sci. 2022;119:e2204336119 https://doi.org/10.1073/pnas.2204336119. Epub 2022 Jul 15

Article CAS PubMed PubMed Central Google Scholar

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl J Med. 2021;384:8082. https://doi.org/10.1056/NEJMc2032195. mRNA-1273 Study Group

Article CAS PubMed Google Scholar

Doria-Rose N, Suthar MS, Makowski M, OConnell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N. Engl J Med. 2021;384:225961. https://doi.org/10.1056/NEJMc2103916. mRNA-1273 Study Group

Article PubMed PubMed Central Google Scholar

Huang A, Cicin-Sain C, Pasin C, Epp S, Audig A, Mller NJ, et al. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transpl Cell Ther. 2022;28:214.e1214.e11. https://doi.org/10.1016/j.jtct.2022.01.019

Article CAS Google Scholar

Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, et al. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022;185:872880.e3. https://doi.org/10.1016/j.cell.2022.01.011

Article CAS PubMed PubMed Central Google Scholar

Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl J Med. 2022;387:2134. https://doi.org/10.1056/NEJMoa2203965

Article CAS PubMed Google Scholar

Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl J Med. 2022;386:220112. https://doi.org/10.1056/NEJMoa2118946

Article CAS PubMed Google Scholar

Kimura M, Ferreira VH, Kothari S, Pasic I, Mattsson JI, Kulasingam V, et al. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Transplant Cell Ther. 2022 Jul:S2666-6367(22)01510-X. https://doi.org/10.1016/j.jtct.2022.07.024

Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021;8:e681e683. https://doi.org/10.1016/S2352-3026(21)00274-X

Article CAS PubMed PubMed Central Google Scholar

Ahmed-Belkacem A, Redjoul R, Brillet R, Ahnou N, Leclerc M, Lpez-Molina DS, et al. Third Early Booster Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses. 2022;14:1928 https://doi.org/10.3390/v14091928

Article CAS PubMed PubMed Central Google Scholar

Maneikis K, ablauskas K, Ringeleviit U, Vaiteknait V, ekauskien R, Kryauskait L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583e592. https://doi.org/10.1016/S2352-3026(21)00169-1

Article CAS PubMed PubMed Central Google Scholar

Uyemura BS, Abid MA, Suelzer E, Abid MB Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients - targeting the target antigen. Bone Marrow Transplant. 2022 Aug:15. https://doi.org/10.1038/s41409-022-01795-3

Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022 Sep. https://doi.org/10.1016/S1473-3099(22)00642-9

Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139:143951. https://doi.org/10.1182/blood.2021013768

Article CAS PubMed PubMed Central Google Scholar

La J, Wu JT, Branch-Elliman W, Huhmann L, Han SS, Brophy MT, et al. Increased COVID-19 Breakthrough Infection Risk in Patients with Plasma Cell Disorders. Blood. 2022 May:blood.2022016317. https://doi.org/10.1182/blood.2022016317

Jimnez M, Roldn E, Fernndez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022;6:77484. https://doi.org/10.1182/bloodadvances.2021006101

Article CAS PubMed PubMed Central Google Scholar

McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:6304. https://doi.org/10.1038/s41586-020-03041-6

Article CAS PubMed Google Scholar

Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:4350. https://doi.org/10.1126/science.abm3425

Article CAS PubMed Google Scholar

Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, et al. Immune Assays Team; the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; and the United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol. 2022;7:19962010. https://doi.org/10.1038/s41564-022-01262-1

Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:161824. https://doi.org/10.1016/S0140-6736(22)00327-0

Article CAS PubMed PubMed Central Google Scholar

Misra A, Theel ES. Immunity to SARS-CoV-2: what do we know and should we be testing for it? J Clin Microbiol. 2022;60:e0048221.

Article PubMed Google Scholar

Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59:e03149.

Article CAS PubMed PubMed Central Google Scholar

Saker K, Escuret V, Pitiot V, Massardier-Pilonchry A, Paul S, Mokdad B, et al. Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers. J Clin Microbiol. 2021;60:e017462.

Google Scholar

Swadba J, Anyszek T, Panek A, Chojta A, Wyrzykowska K, Martin E. Head-to-head comparison of 5 anti-SARS-CoV-2 assays performance in one hundred COVID-19 vaccinees, over an 8-month course. Diagnostics. 2022;12:1426.

Article PubMed PubMed Central Google Scholar

Danese E, Montagnana M, Salvagno G, Gelati M, Peserico D, Pighi L, et al. Comparison of five commercial anti-SARS- CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA. J Med Biochem. 2021;40:33540.

Article CAS PubMed PubMed Central Google Scholar

Camacho J, Albert E, Zulaica J, lvarez-Rodrguez B, Rusu L, Olea B, et al. A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti-spike antibodies according to SARS-CoV-2 vaccination and infections status. J Med Virol. 2023;95:e28397.

Article CAS PubMed Google Scholar

See the original post here:
SARS-CoV-2-reactive antibody waning, booster effect and ... - Nature.com